Literature DB >> 31844168

Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data.

Ashish Sharma1, M Hafeez Faridi2, Nilesh Kumar3, Nikulaa Parachuri3, Rohini Sharma4, Baruch D Kuppermann5, Francesco Bandello6, Anat Loewenstein7, Carl D Regillo8.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 31844168      PMCID： PMC7411014          DOI： 10.1038/s41433-019-0745-z

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  6 in total

Review 1.  Current and Novel Therapeutic Approaches for Treatment of Diabetic Macular Edema.

Authors:  Muhammad Z Chauhan; Peyton A Rather; Sajida M Samarah; Abdelrahman M Elhusseiny; Ahmed B Sallam
Journal:  Cells       Date:  2022-06-17       Impact factor: 7.666

2.  Clinical efficacy and safety of Razumab® (CESAR) study: Our experience with the world's first biosimilar Ranibizumab.

Authors:  Lalit Verma; Mithun Thulasidas; Ajay Purohit; Avnindra Gupta; Ritesh Narula; Dinesh Talwar
Journal:  Indian J Ophthalmol       Date:  2021-02       Impact factor: 1.848

Review 3.  Future of anti-VEGF: biosimilars and biobetters.

Authors:  Monika Kapur; Suvansh Nirula; Mayuresh P Naik
Journal:  Int J Retina Vitreous       Date:  2022-01-04

4.  Ranizurel safety evaluation in real-world -(RaSER) study.

Authors:  Ashish Sharma; Jayshree Arunaprakash; Atheeshwar Das; Ashraya Nayaka; Nilesh Kumar; Nikulaa Parachuri; Baruch D Kuppermann
Journal:  Am J Ophthalmol Case Rep       Date:  2022-02-02

Review 5.  Treatment Landscape of Macular Disorders in Indian Patients with the Advent of Razumab™ (World's First Biosimilar Ranibizumab): A Comprehensive Review.

Authors:  Shashikant Sharma; Tanishq Sharma; Somdutt Prasad; Mahesh Gopalakrishnan; Alok Chaturvedi
Journal:  Ophthalmol Ther       Date:  2021-06-21

6.  Ranibizumab Biosimilar (Razumab) vs Innovator Ranibizumab (Lucentis) in neovascular age-related macular degeneration (n-AMD)- efficacy and safety (BIRA study).

Authors:  Ashish Sharma; Nilesh Kumar; Nikulaa Parachuri; Francesco Bandello; Baruch D Kuppermann; Anat Loewenstein
Journal:  Eye (Lond)       Date:  2021-06-22       Impact factor: 4.456
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.